Dogwood Therapeutics outlines 2026 plans for pain pipeline

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialDogwood Therapeutics ( (DWTX) ) has shared an announcement. In a January 20, 2026 shareholder letter, Dogwood Therapeutics reported that during 2025 it advanced its non-opioid pain and neuropathy pipeline by recruiting over 100 patients into its Phase 2b HALT-CINP study of Halneuron, securing a royalty-free global license to develop and commercialize SP16 IV for cancer-related pain and neuropathy, progressing a chemically synthesized version of Halneuron to lower manufacturing costs and improve yields, and filing new intellectual property that could extend Halneuron protection to 2046. Looking ahead through 2026, the company plans to deliver final Phase 2b Halneuron data in the third quarter following a January financing, file an IND for SP16 with the FDA and begin Phase 1b dosing by mid-2026, conduct a bridging study between biological and synthetic Halneuron, and submit end-of-Phase 2, manufacturing and Phase 3 development plans to regulators, milestones that, if achieved, would significantly advance its lead assets toward late-stage development in the competitive non-opioid cancer pain market. The most recent analyst rating on (DWTX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Dogwood Therapeutics stock, see the DWTX Stock Forecast page. Spark’s Take on DWTX Stock According to Spark, TipRanks’ AI Analyst, DWTX is a Neutral. The score is weighed down primarily by weak financial performance (pre-revenue, widening losses, and rising cash burn) and a bearish technical trend (price well below major moving averages with negative MACD). Corporate events provide some offset through improved funding runway, but dilution risk and limited support from valuation metrics keep the overall score below average. To see Spark’s full report on DWTX stock, click here. More about Dogwood Therapeutics Dogwood Therapeutics, Inc. (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on creating non-opioid medicines for pain and neuropathic disorders, particularly cancer-related pain and chemotherapy-induced neuropathic pain. Its pipeline is led by Halneuron®, a Phase 2b NaV1.7 analgesic with FDA fast track designation for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist intended to treat neuropathy and repair nerve damage following chemotherapy; the company’s largest shareholder is affiliated with CK Life Sciences Int’l., (Holdings) Inc., listed in Hong Kong. Average Trading Volume: 57,474 Technical Sentiment Signal: Sell Current Market Cap: $89.19M Learn more about DWTX stock on TipRanks’ Stock Analysis page.